SWS Partners Reduces Stock Holdings in Guardant Health, Inc. $GH

SWS Partners trimmed its position in shares of Guardant Health, Inc. (NASDAQ:GH) by 18.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 77,209 shares of the company’s stock after selling 17,347 shares during the quarter. Guardant Health comprises 1.5% of SWS Partners’ holdings, making the stock its 17th biggest holding. SWS Partners’ holdings in Guardant Health were worth $7,886,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the company. Emerald Advisers LLC grew its stake in shares of Guardant Health by 24.8% during the 3rd quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock worth $54,558,000 after acquiring an additional 173,281 shares during the period. Knights of Columbus Asset Advisors LLC purchased a new stake in Guardant Health in the 3rd quarter worth about $1,554,000. Edgestream Partners L.P. raised its stake in Guardant Health by 147.3% in the 2nd quarter. Edgestream Partners L.P. now owns 50,519 shares of the company’s stock valued at $2,629,000 after acquiring an additional 30,094 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Guardant Health by 54.4% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock valued at $18,835,000 after acquiring an additional 106,263 shares during the period. Finally, State of Wyoming purchased a new stake in Guardant Health during the second quarter valued at about $567,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Stock Down 1.3%

Shares of NASDAQ GH opened at $91.15 on Thursday. The company has a market cap of $11.96 billion, a P/E ratio of -27.54 and a beta of 1.67. Guardant Health, Inc. has a 52 week low of $36.36 and a 52 week high of $120.74. The business has a 50-day simple moving average of $97.96 and a two-hundred day simple moving average of $92.15.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analysts’ expectations of $269.74 million. During the same quarter in the previous year, the company posted ($0.62) EPS. The firm’s revenue for the quarter was up 39.4% on a year-over-year basis. Equities research analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Activity

In related news, Director Medina Manuel Hidalgo sold 1,300 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $91.54, for a total transaction of $119,002.00. Following the completion of the transaction, the director owned 1,193 shares of the company’s stock, valued at approximately $109,207.22. The trade was a 52.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Musa Tariq sold 348 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $88.09, for a total transaction of $30,655.32. Following the sale, the director directly owned 8,394 shares in the company, valued at $739,427.46. This trade represents a 3.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 23,250 shares of company stock worth $2,512,917 in the last three months. Insiders own 6.10% of the company’s stock.

Wall Street Analyst Weigh In

GH has been the subject of a number of research reports. Robert W. Baird started coverage on shares of Guardant Health in a research report on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Guardant Health from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. UBS Group restated a “buy” rating and set a $175.00 price target on shares of Guardant Health in a research note on Friday, January 30th. Raymond James Financial reaffirmed an “outperform” rating and issued a $129.00 price objective on shares of Guardant Health in a report on Monday, February 23rd. Finally, Canaccord Genuity Group lifted their price objective on shares of Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Twenty analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $125.95.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.